Deutsche Märkte geschlossen

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
25,09+1,42 (+6,00%)
Börsenschluss: 04:00PM EST
25,09 0,00 (0,00%)
Nachbörse: 04:08PM EST

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490
https://www.springworkstx.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter207

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Saqib Islam J.D.CEO & Director1,13MN/A1970
Mr. Francis I. Perier Jr., M.B.A.Chief Financial Officer674,85kN/A1960
Dr. Badreddin Edris Ph.D.Chief Operating Officer844,74kN/A1987
Mr. Bhavesh AsharChief Commercial Officer821,61kN/A1966
Mr. Michael P. NofiChief Accounting OfficerN/AN/A1971
Ms. Kim DiamondVP of Communications & Investor RelationsN/AN/AN/A
Mr. Herschel S. Weinstein J.D.Gen. Counsel & Sec.N/AN/A1956
Mr. Daniel J. PichlChief People OfficerN/AN/A1983
Dr. L. Mary Smith PH.D.Chief Devel. OfficerN/AN/A1967
Dr. James Cassidy M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate Governance

SpringWorks Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 10. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.